Wuhan YZY Biopharma Co (HKSE:02496) ROCE %: -6,867.95% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Wuhan YZY Biopharma Co ROCE %?

Wuhan YZY Biopharma Co HKSE:02496 ROCE % is -6,867.95% as of Dec. 2025. The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Wuhan YZY Biopharma Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -6,867.95%.

Wuhan YZY Biopharma Co  (HKSE:02496) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Wuhan YZY Biopharma Co ROCE % Related Terms

Wuhan YZY Biopharma Co ROCE % Historical Data

* Premium members only.

The historical data trend for Wuhan YZY Biopharma Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuhan YZY Biopharma Co ROCE % Chart

Wuhan YZY Biopharma Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
-93.23 -119.12 -131.95 -87.96 -298.59

Wuhan YZY Biopharma Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial -163.03 -139.03 -39.82 -211.06 -6,867.95

Wuhan YZY Biopharma Co ROCE % Calculation

Wuhan YZY Biopharma Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-88.134/( ( (285.968 - 198.732) + (193.335 - 221.537) )/ 2 )
=-88.134/( (87.236+-28.202)/ 2 )
=-88.134/29.517
=-298.59 %

Wuhan YZY Biopharma Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-51.544/( ( (261.926 - 232.223) + (193.335 - 221.537) )/ 2 )
=-51.544/( ( 29.703 + -28.202 )/ 2 )
=-51.544/0.75049999999999
=-6,867.95 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -6,867.95% mean?
Wuhan YZY Biopharma Co (HKSE:02496) has a ROCE % of -6,867.95% as of Dec. 2025.
Is Wuhan YZY Biopharma Co's ROCE % too high?
Wuhan YZY Biopharma Co's current ROCE % is -6,867.95%.
How does Wuhan YZY Biopharma Co's ROCE % compare to VRTX and REGN?
Wuhan YZY Biopharma Co's ROCE % of -6,867.95% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Wuhan YZY Biopharma Co's current ROCE % is -6,867.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan YZY Biopharma Co stock overvalued right now?
Wuhan YZY Biopharma Co (HKSE:02496) has a current ROCE % of -6,867.95%. The current ROCE % is -6,867.95%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Wuhan YZY Biopharma Co (HKSE:02496), the current ROCE % is -6,867.95% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Wuhan YZY Biopharma Co Business Description

Address No. 666 Gaoxin Road, Building C2-1, Optics Valley Bio-City, East Lake High Tech Development Zone, Hubei Province, Wuhan, CHN
Wuhan YZY Biopharma Co Ltd is a biotechnology company dedicated to developing bispecific antibody (BsAb)- based therapies. The Company has been forward-looking in deploying its presence in several therapeutic fields, including but not limited to tumor-associated complications, tumors, ophthalmology, and autoimmune diseases. The Company also proactively established several self-developed technology platforms, such as Y-BODY, Check-Body, and Nano-Ybody, promoting the development of more candidates to clinical stages with high efficiency.